One famous HIV clinician/clinical researcher likens co-formulated TDF/FTC/EFV (Atripla) to a "Godzilla," so dominant has the treatment become as initial therapy for HIV. He bases his comments on this study done at his institution, showing that in 2007, fully 85% of patients starting treatment in their clinic began TDF/FTC/EFV.
First, there's the requirement for written informed consent, something that every state (except a couple) has wisely abandoned. Second, it's more than a testing law -- it's also an HIV privacy law, which is arguably unnecessary in this post HIPAA era and has all sorts of unintended consequences.
Just back from IAS 2011 (which was followed, I'm thrilled to say, with a visit to perhaps the most beautiful region in the world). Here is a Really Rapid ReviewTM of the meeting, with apologies ahead of time for lack of organization and (even more likely) leaving out something important. FYI, the abstracts are online here; I'm sure there's a place on the meeting homepage that has the same link, but I can't seem to find it.
Groundbreaking results of two large pre-exposure prophylaxis (PrEP) studies may lead to a new prevention option to reduce HIV transmission. Data released on two PrEP studies showed high levels of protection against HIV infection when tenofovir (Viread) or Truvada (tenofovir and emtricitabine) were taken daily by HIV-uninfected individuals at high risk for infection.
In my current practice, every day there is at least one man over the age of 50 asking for an erectile dysfunction (ED) medication. It seems to have become an epidemic. Or it is just more openly discussed. Or both.
As part of the usual flurry of studies released just before major scientific meetings, results of two pre-exposure prophylaxis (PrEP) trials in heterosexual men and women have just been made public:
The result of the above stellar behavior? I would do virtually anything to try and help her. Back in the late 1990s, when she was very sick with AIDS, one of my fellows said it best: "There's just something about her that makes you want to take care of her." Exactly.
It was the peak time for the cherry blossoms in Washington, D.C. -- or so I was told. I only caught a glimpse of them from the Metro as I was riding in from Reagan National, and a few times out the window of the hotel conference room (along with rain and even a brief burst of hail during that tempestuous spring weekend). But I wasn't in town for sightseeing: I was one of about 15 individuals from around the country selected to participate in the Training of Trainers program, a component of the National Association of Social Workers' HIV/AIDS Spectrum: Mental Health Training and Education of Social Workers Project.
A while back, after a challenging day in the office, I came home to the pleasure of reading the Winter 2011 edition of HIV Specialist, the magazine of the American Academy of HIV Medicine (AAHIVM). Of particular interest to my weary brain was an article by Bruce J. Packett II entitled "The Evolution of Viral Load Technologies."
Of the HIV medications in development with potential activity against highly resistant HIV (i.e., patients with GSS=0), two may become available within the next year: ibalizumab (formerly TNX-355), a monoclonal antibody currently under development by TaiMed Biologics, and dolutegravir (formerly GSK1349572), a second-generation integrase inhibitor made by ViiV Healthcare).